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Adenosine-to-inosine (A-to-I) RNA editing, which is catalyzed by adenosine deaminase 
acting on RNA (ADAR) enzymes, is the most frequent type of RNA editing in mammals. The 
conversion of nucleotides possibly affects amino acid sequence, splicing and microRNA 
(miRNA) targeting. The purpose of this study is to clarify the impact of RNA editing on 
expression of pharmacokinetics- and pharmacodynamics-related genes, focusing on human 
aryl hydrocarbon receptor (AhR) and dihydrofolate reductase (DHFR). First, it was revealed 
that ADAR1-mediated RNA editing negatively regulates AhR expression by creating miR-378 
binding site in the 3’-untranslated region (3’-UTR) in human hepatocellular carcinoma-
derived Huh-7 cells. The down-regulation of AhR attenuated 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD)-mediated induction of CYP1A1, a downstream gene of AhR. In human liver 
samples, high editing levels in the 3’-UTR of AhR and a significant inverse association 
between miR-378 and AhR protein levels were observed, suggesting the RNA editing-
dependent down-regulation of AhR by miR-378 contributes to the variability in the hepatic 
AhR expression. Second, it was revealed that ADAR1-mediated RNA editing positively 
regulates DHFR expression in human breast cancer-derived MCF-7 cells by destroying miR-
25-3p and miR-125a-3p binding sites in the 3’-UTR. The up-regulation of DHFR enhanced 
cellular proliferation and resistance to methotrexate. The editing levels in breast cancer tissues 
were higher than in normal tissues, suggesting a possibility that the hyper-editing of DHFR 
transcript would be responsible for the increased DHFR expression. Taken together, this study 
demonstrated the biological significance of RNA editing in drug response.  
 
Background 
RNA editing is a post-transcriptional process that alters nucleotide sequence of RNA 
transcripts. In mammals, the most common type of RNA editing is A-to-I editing, which is 
catalyzed by ADAR enzymes. They convert adenosine in double-stranded RNA structures 
into inosine by hydrolytic deamination. Since much of the cellular machinery treats inosine as 
guanine, the conversion of nucleotides possibly changes amino acid sequence, splicing, 
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miRNA targeting or miRNA maturation. In vertebrates, two functional members of the ADAR 
family, ADAR1 and ADAR2, are ubiquitously expressed. It became apparent that disrupted 
RNA editing or abnormal ADAR expression are associated with several diseases, including 
cancer, neurological disorders, metabolic diseases, viral infections, and autoimmune 
disorders. The purpose of this study is to clarify the biological significance of RNA editing in 
pharmacokinetics and pharmacodynamics-associated genes, focusing on AhR and DHFR, 
because RADAR, a database of RNA editing sites, indicates that the 3’-UTRs of these gene 
transcripts are subjected to RNA editing. In general, 3’-UTR includes binding sites for 
miRNA, which silences gene expression via translational repression or mRNA degradation. 
Accordingly, a possibility that RNA editing regulates expression of AhR and DHFR by 
altering miRNA binding site was examined.  
 
Down-regulation of human aryl hydrocarbon receptor expression by RNA editing in 
human liver 
AhR is a ligand-activated transcription factor that regulates the expression of xenobiotic-
metabolizing enzymes, including CYP1A1, CYP1A2 and CYP1B1. By direct sequencing of 
AhR cDNA and genomic DNA, 38 RNA editing sites were identified in the 3’-UTR of AhR in 
human hepatocellular carcinoma-derived Huh-7 cells. Knockdown of ADAR1 resulted in 
decrease in the RNA editing levels and increase in AhR protein levels, but not mRNA levels, 
indicating that ADAR1 negatively regulates AhR expression in a post-transcriptional manner. 
TCDD-mediated induction of CYP1A1, a downstream gene of AhR, was augmented by 
ADAR1 knockdown, suggesting that RNA editing affected the expression of P450 isoform. It 
was surmised that A-to-I RNA editing created miRNA targeting sites in AhR mRNA. By in 
silico analysis, miR-378 was predicted as a candidate miRNA whose binding affinity to the 
edited AhR 3’-UTR would be higher than that to the unedited 3’-UTR of AhR. Interestingly, 
overexpression of miR-378 decreased AhR protein expression levels, and the miR-378-
dependent downregulation of AhR was abolished by knockdown of ADAR1. The results 
indicated that the mechanism of the ADAR1-mediated downregulation of AhR would be 
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attributed to the creation of the miR-378 recognition site in the 3’-UTR of AhR. The 
interindividual differences in the RNA editing levels within the 3’-UTR of AhR in a panel of 
32 human liver samples were relatively small, whereas the differences in ADAR1 expression 
were large (220-fold). In the human liver samples, a significant inverse association was 
observed between the miR-378 and AhR protein levels, suggesting that the RNA editing-
dependent down-regulation of AhR by miR-378 contributes to the variability in the 
constitutive expression of AhR in human liver. Taken together, it was found that A-to-I RNA 
editing regulates the expression of AhR by creating miR-378 binding sites. The mechanism 
contributes to the interindividual variability in AhR expression in human livers. This study is 
the first to prove that RNA editing modulates the potency of xenobiotic metabolism in the 
human liver.  
 
Up-regulation of dihydroforate reductase in human breast cancer by RNA editing 
DHFR plays a key role in folate metabolism, and is a target of methotrexate. In human 
breast adenocarcinoma-derived MCF-7 cells, 26 RNA editing sites were identified in the 3’-
UTR of DHFR. Knockdown of ADAR1 decreased the RNA editing levels in the 3’-UTR of 
DHFR in MCF-7 cells, and resulted in the decrease of DHFR mRNA and protein levels. By 
using -amanitin, a transcriptional inhibitor, it was revealed that the edited DHFR mRNA was 
more slowly degraded than the non-edited mRNA, suggesting that DHFR mRNA are 
stabilized by RNA editing. Thus, it was found that ADAR1 up-regulates DHFR expression by 
stabilization of mRNA. miR-25-3p and miR-125a-3p were predicted, by a computational 
analysis, to bind to the non-edited 3’-UTR of DHFR but not to the edited sequence. The 
decrease in DHFR expression by the knockdown of ADAR1 was restored by inhibition of 
these miRNAs, suggesting that RNA editing-mediated up-regulation of DHFR requires the 
function of these miRNAs. Interestingly, the knockdown of ADAR1 decreased cell viability 
and increased the sensitivity to methotrexate of MCF-7 cells. ADAR1 expression levels and 
the RNA editing levels in the 3’-UTR of DHFR in breast cancer tissues were higher than 
those in adjacent normal tissues. Collectively, ADAR1 positively regulates the expression of 
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DHFR through RNA editing by disrupting the binding of miR-25-3p and miR-125a-3p to the 
3’-UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. This study 
could provide new insights into the regulatory mechanism of DHFR expression and the role 
of RNA editing in cancer progression and methotrexate response. ADAR1 may be a potential 
anti-tumor target for use with anti-folate compounds including methotrexate. 
 
Conclusion 
In this dissertation, it was clarified that RNA editing modulates AhR and DHFR expression 
by creating and destroying miRNA recognition sites in the 3’-UTRs, respectively. This study 
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RNA編集の一種である A-to-I RNA editing は遺伝子の発現および機能に影響を与え




を制御する転写因子である AhR が、ヒト肝臓中において ADAR1 によって RNA編
集を受けることで、microRNAによる発現抑制を受けることを見出した。この発現制
御は AhR 下流遺伝子である CYP 分子種の発現にも影響を及ぼした。葉酸代謝の鍵
分子であり、癌化学療法剤メトトレキサートの標的である DHFR が、ヒト乳がん細




たものであり、博士 (創薬科学) に値すると判定した。 
 
